17-DMAG, a potent HSP90 inhibitor, displays time-of-day–specific action on melanoma tumors in mice but is less effective on clock mutant tumors even in a wild-type host, underscoring the importance of circadian regulation within the tumor. Here, HSP90AA1 is linked to melanoma.